Seeking Alpha

Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the...

Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the company's Stratify JCV Antibody Elisa testing service. The approval means doctors can now test for the risk of a potentially fatal brain infection caused by Tysabri, a multiple sclerosis treatment sold by Biogen Idec (BIIB) and Elan (ELN).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs